Blue Jet Healthcare drops its ₹1,000 cr Vizag project
Management is shifting to de-bottlenecking after its CDMO pipeline shrank from 20 active projects to 4-5.
— 1 earlier story on Blue Jet Healthcare Ltd. →What's new
- Capex focus shifts from the ₹1,000 cr Vizag project to de-bottlenecking and environmental infrastructure.
- The active CDMO pipeline has shrunk to 4-5 key projects from 20 previously reported RFPs.
- Q2 revenue of ₹161 cr included a ₹20-25 cr logistical delay that is now resolved.
Why this matters
The retreat from a major capital project and the sharp contraction in the project pipeline signal a cooling of growth. Investors must weigh the stability of Contrast Media margins against the reduced visibility in the CDMO business.
What we're watching
- The timeline for the single pharma intermediate molecule entering commercial production.
- Whether the shift in capex priorities signals a broader change in long-term capacity plans.
- Sustainability of the 33-35% margin guidance for the Contrast Media segment.
The full read
Blue Jet Healthcare is recalibrating its growth strategy. The company is stepping back from its ₹1,000 crore Vizag capex plan, opting instead to focus on de-bottlenecking and environmental infrastructure for FY26. This pivot coincides with a contraction in the CDMO pipeline, which has dropped to 4-5 key projects from the 20 active RFPs previously reported. While the company posted an H1 EBITDA margin of 34.4% and a net profit of ₹72 crore, the operational narrative has shifted. Q2 revenue of ₹161 crore was hampered by a ₹20-25 crore logistical delay, which management claims is now resolved. Looking ahead, the company expects Contrast Media margins to stabilize in the 33-35% range as Unit 2 capacity comes online. One pharma intermediate molecule is slated for commercial production within 12 months. The open question is whether these changes represent a temporary pause or a permanent reduction in the company's growth trajectory.
Questions answered
- What is happening with the ₹1,000 crore Vizag project?
- Blue Jet is moving away from the project. Management is now prioritizing de-bottlenecking and environmental infrastructure for FY26.
- How did the CDMO pipeline change?
- The pipeline has narrowed to 4-5 key projects. This is a reduction from the 20 active RFPs the company cited in prior quarters.
- What impacted the Q2 revenue figures?
- Revenue of ₹161 crore was hit by a logistical delay of ₹20-25 crore. The company states this issue is now resolved.
- What are the expectations for Contrast Media margins?
- Margins are expected to stabilize between 33% and 35% in the second half of the year. This assumes the new Unit 2 capacity scales up as planned.
Story so far
All notes on BLUEJET →- 25 May 2026 · 6:08 PM IST Blue Jet Healthcare drops its ₹1,000 cr Vizag project
- 1d ago Blue Jet sets a three-year, ₹1,000 cr timeline for its Vizag pivot